Prevention of Thromboembolic Events in Total Knee Replacement Patients

NCT03393481 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Trial cancelled before First Patient First Visit (no patient enrolled)

Conditions

Thrombotic Disorders

Interventions

DRUG: MAA868
DRUG: Enoxaparin

Sponsor

Novartis Pharmaceuticals